Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Northend, Michael; Wilson, William; Osborne, Wendy; Fox, Christopher P; Davies, Andrew J; El-Sharkawi, Dima; Phillips, Elizabeth H; Sim, Hau Wui; Sadullah, Shalal; Shah, Nimish; Peng, Ying Ying; Qureshi, Iman; Addada, Juanah; Mora, Rocio Figueroa; Phillips, Neil; Kuhnl, Andrea; Davies, Elizabeth; Wrench, David; McKay, Pamela; Karpha, Indrani; Cowley, Anna; Karim, Richard; Challenor, Sarah; Singh, Vikram; Burton, Cathy; Auer, Rebecca; Williams, Chris; Cunningham, Joel; Broom, Angus; Arasaretnam, Anita; Roddie, Claire; Menne, Tobias; Townsend, William

Affiliation

University College Hospital; Cancer Research United Kingdom; UCL Cancer Trials Centre; The Newcastle-upon-Tyne Hospitals NHS Foundation Trust; Nottingham University Hospitals NHS Trust; University of Southampton; Southampton General Hospital; The Royal Marsden Hospital; The Christie Hospital; University of Manchester; Northwick Park Hospital; James Paget University Hospital; Norfolk & Norwich University Hospital; St George's Hospital; University Hospitals Birmingham NHS Foundation Trust; University Hospital of Derby & Burton NHS Foundation Trust; University Hospitals of North Midlands NHS Trust; King's College Hospital NHS Foundation Trust; Manchester University NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Beatson West of Scotland Cancer Centre; The Clatterbridge Cancer Centre; East Sussex Healthcare NHS Trust; Dorset County Hospital; Royal Cornwall Hospital; Liverpool University Hospital NHS Foundation Trust; Leeds Teaching Hospitals NHS Trust; Bart's Health NHS Trust; Northumbria Healthcare NHS Foundation Trust; Western General Hospital; Brighton & Sussex University Hospitals NHS Trust

Publication date

2022-05-09

Subject

Haematology
Oncology. Pathology.

Metadata

Show full item record

Abstract

No abstract available

Citation

Northend M, Wilson W, Osborne W, Fox CP, Davies AJ, El-Sharkawi D, Phillips EH, Sim HW, Sadullah S, Shah N, Peng YY, Qureshi I, Addada J, Mora RF, Phillips N, Kuhnl A, Davies E, Wrench D, McKay P, Karpha I, Cowley A, Karim R, Challenor S, Singh V, Burton C, Auer R, Williams C, Cunningham J, Broom A, Arasaretnam A, Roddie C, Menne T, Townsend W. Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood Adv. 2022 May 10;6(9):2920-2926. doi: 10.1182/bloodadvances.2021005953.

Type

Correspondence